AFX.XETRA

Carl Zeiss Meditec's ceiling is real but capped: it operates inside a mature, demographically-driven pie rather than creating a new market. The report leans on Alcon's estimate that the ophthalmic surgical market is worth about $14bn and will grow 4%–6% a year from 2025 to 2030, driven by aging-related cataract demand, retinal procedures, glaucoma interventions and refractive technology upgrades. That is a structurally attractive but finite tailwind; as the report frames it, this makes Carl Zeiss Meditec a demographic-growth company at the top layer, not the architect of a new addressable category. Within that pie the company does lift its own ceiling through premium mix and share. The FY2024/25 annual report shows ophthalmology at about 77% of revenue and microsurgery around 23%, with recurring revenue climbing from 9% in 2002/03 to roughly 50% today, deepening monetization of an installed base spanning more than 15 million cataract surgeries a year. But premium gains in refractive and microsurgery compound an existing market; they do not open a new one. The same demographic engine that underwrites demand also caps it — 4%–6% category growth cannot deliver the multi-fold, new-market expansion an LTGG ceiling demands, and the China VBP shock proves policy can compress the premium slice even as procedure volumes keep rising. Honest verdict: a growing existing pie, not a newly unlocked market — for an LTGG ceiling hunting a new-market 5x, a have-not.

No — Carl Zeiss Meditec's revenue cannot double in five years, and the franchise is currently shrinking, not compounding. The H1 FY2025/26 report shows revenue of €991.0m, down 5.7%, after a Q1 that fell 4.8% to €467.0m. Management has cut full-year guidance to €2.15bn–€2.20bn, below FY2024/25's €2,227.6m. Decisively, even the report's own optimistic FY2028/29 scenario — the one assuming China relisting works, US equipment recovers and microsurgery stays healthy — reaches only about €2.60bn–€2.70bn. Against the €2,227.6m FY2024/25 base, that is roughly +20% over five years, not the +100% a double demands; the base case is weaker still at €2.45bn–€2.55bn. This is not a volume-doubling story but a margin-and-mix recovery, where the prize is lifting adjusted EBITA margin back toward the mid-teens from the 6.1% H1 trough, not multiplying the top line. Even the reported FY2024/25 base was flattered by DORC's acquired revenue, so on an organic footing the gap to a double is wider still. What growth exists hinges on rebuilding the China VBP channel — the successor bifocal IOL only just obtained registration approval, and the next tender's price and profitability are still unknown. A company whose largest market, China at about 25% of sales, is being reconstructed under tender-driven price compression has no realistic route to double revenue over the five-year horizon the report models. The arithmetic is unambiguous and management's own guidance confirms it. Verdict: a clear have-not on the LTGG five-year doubling test.

On a second growth curve, Carl Zeiss Meditec scores low: no distinct, independent engine is ready to take the baton. The obvious candidate, microsurgery, is not it. The H1 FY2025/26 report shows microsurgery at €237.2m against ophthalmology's €753.8m — around 23% of sales — and it is a mature leadership business where management claims the number-one position, not an emerging high-growth curve; it grew just 1.8% currency-adjusted in the half. The second candidate, recurring revenue rising from 9% in 2002/03 to roughly 50% today, is real but is a mix shift inside the existing core — consumables, implants, software and service on the same installed base — not a separate business with its own trajectory, and its two-decade-long climb is a gradual improvement rather than a fresh S-curve. What actually pulls the company out of the trough is the same ophthalmology franchise being repaired: relisting the successor bifocal IOL into China's next VBP cycle and executing the ProfitUp restructuring for more than €200m of annual earnings contribution by FY2028/29. Even DORC, the €1,023.7m retinal-surgery acquisition, broadens the existing ophthalmology portfolio rather than igniting a new curve. Every lever in the report points backward to fixing curve one, not forward to a second S-curve compounding independently while the first matures — the opposite of what the baton-pass test rewards. Verdict: no genuine second curve exists today — on the LTGG baton-pass axis, a have-not.

Carl Zeiss Meditec's moat is real and deep per account, but narrowing at its most profitable edge. The advantage is genuine. The FY2024/25 annual report and investor materials note ZEISS optics sit in the surgeon's line of sight across more than 15 million cataract surgeries and more than 10 million neurosurgical procedures a year; recurring revenue near 50% deepens installed-base lock-in across consumables, implants and service; and R&D running in the mid-teens as a percentage of revenue, with a target above 16%, sustains technology leadership in categories with long product cycles. That is a workflow-and-brand moat, not a commodity position. But it is eroding where it matters most. In ophthalmology, Carl Zeiss Meditec is the challenger, not the incumbent — Alcon is the scale leader, generating $5.751bn of surgical revenue in 2025 and spreading R&D and commercial infrastructure across a far broader base. More tellingly, management itself described a period of "vulnerability" in China because it had not localized manufacturing fast enough, just as VBP compresses premium pricing in exactly the IOL and refractive mix where the firm historically earned premium economics. A moat management publicly concedes is breached in its largest market, at about 25% of sales, is not widening. It is deeper per account than a pure scale moat, yet actively compressing under China policy. Verdict: a real moat, but a narrowing one — on the LTGG durability axis, a qualified have, not a clear one.

On adaptive genes, Carl Zeiss Meditec scores moderately: it does reinvent, but reactively, forced by events rather than ahead of them. The evidence of adaptation is concrete. It broadened its ophthalmology portfolio into retinal surgery and vitrectomy through the €1,023.7m DORC acquisition, effective April 2024. Facing the margin collapse, management launched the ProfitUp restructuring, targeting more than €200m of additional annual earnings contribution by FY2028/29, with up to 1,000 roles affected and up to €150m of cumulative one-off costs and CapEx. Confronting the China shock, it suspended FY2025/26 guidance in January 2026, reset it lower by May, and candidly admitted — in management's own words — a period of "vulnerability" because it had not localized manufacturing fast enough. That candor earns real credit; the report notes the company stopped defending old guidance and accepted the need for cost, footprint and portfolio surgery rather than waiting for demand to rescue margins. But these are responses to bad news arriving late, not self-disruption ahead of the curve. The China localization lag, in a market that is about 25% of sales, should arguably have been addressed earlier, and ProfitUp is damage control, not pre-emptive reinvention. The genes for adaptation and honest course-correction are present and above the medtech norm, yet the pattern is evolutionary and event-driven. Honest verdict: moderate, evolutionary and reactive reinvention — on the LTGG bold-reinvention axis, a moderate, not standout, have.

On stewardship the franchise lands in the middle band: patient controlling ownership offsets genuine instability at the top, and the two roughly cancel. The alignment case is strong. The FY2024/25 annual report and corporate-governance page confirm Carl Zeiss AG holds about 59% of the shares under the Carl Zeiss Foundation — the kind of long-horizon, non-financial owner that can fund a multi-year rebuild without quarterly panic — with related-party transactions registered, audited under German rules and reviewed through a dependency report, and PwC auditing the accounts. Willingness to spend now for later is visible: management chose reprioritization over slash-and-burn, holding R&D in the mid-teens of revenue against a stated above-16% target so this year's margin is not bought at the cost of the next product cycle, and it absorbed the €1,023.7m DORC acquisition, part-funded by a €400m ZEISS shareholder loan, into a weakening cycle for strategic breadth. Against that, the instability is equally real. Per the H1 FY2025/26 report, CFO Justus Felix Wehmer, in place since 2018, now sits beside only an interim management-board chairman, Andreas Pecher, appointed 1 January 2026 after Maximilian Foerst's short tenure ended 31 December 2025; and management's own Q1 commentary conceded it had not localized China manufacturing fast enough. Credible, aligned stewardship — but leadership churn plus a confessed strategic lag pull it off the founder-led ideal. Honest verdict: aligned and patient, yet destabilized — a neutral 5/10.

On the "how much would customers miss it" test the company scores in the upper-middle band: indispensable and sustainable on both prongs, with one structural cap. Indispensability is strong. The ZEISS investor presentation records that more than 15 million cataract surgeries a year are performed with ZEISS surgical systems and more than 10 million neurosurgical procedures use ZEISS surgical microscopes, and management claims the number-one position in microsurgery; a sudden disappearance would genuinely disrupt daily surgical workflows that surgeons train around. Sustainability is sound. Demand is demographic and health-improving — Alcon's estimate puts the ophthalmic surgical market near $14bn growing 4%–6% a year to 2030 on aging-driven cataract, retinal and glaucoma volume — with no dependence on regulatory arbitrage or societal harm, and the FY2024/25 annual report shows recurring revenue near 50%, up from 9% two decades ago, giving a durable installed-base tail. The cap is competitive position. Ophthalmology is the largest segment at about 77% of FY2024/25 revenue, yet here the company is the number-two challenger behind Alcon, whose 2025 surgical revenue of $5.751bn and one-stop breadth mean a rival could partly fill the gap its exit would leave. Microsurgery would be hard to replace; premium ophthalmology, less so. Both prongs are clearly positive, but the number-two standing in its own profit engine keeps this just below maximal. Honest verdict: deeply missed in microsurgery, replaceable at the margin in ophthalmology — a solid 6/10.

On unit economics the score sits in the lower-middle band: real device-and-consumables economics caught in a deep cyclical trough and structurally below an asset-light, software-like model. The trough is severe. The H1 FY2025/26 report shows adjusted EBITA margin collapsing to 6.1% from 10.7%, after a Q1 margin of just 1.7%, against a former 20%-plus operating-margin peak — EBIT margin 22.7% in FY2020/21 and 20.9% in FY2021/22. Operating leverage cuts hard both ways: as the H1 report describes, gross profit falls fast when premium consumable and implant mix slips while operating expenses stay fixed. The business is also inventory-heavy — €538.6m at 31 March 2026, 24.8% of rolling 12-month revenue, up from 22.3% at year-end — capital an incremental-return ideal would not tie up. The partial offset is genuine. Through the cycle, operating cash flow runs above net income: the FY2023/24 annual report pairs €247.3m of operating cash flow with €180.2m profit, and FY2024/25 €209.9m against €142.3m, while recurring revenue near 50% adds ballast. Cash has gone mainly to the €1,023.7m DORC deal and footprint investment, not buybacks. But this remains asset-heavier and lower-margin than the software economics growth investors prize, and the present trough makes it worse, not better, at current scale. FY2024/25 owner earnings of roughly €170m–€175m flatter a year before the full margin trough was visible. Honest verdict: cyclically depressed atop structurally mid-grade economics — a 4/10.

On the ten-year 5x test the answer is, bluntly, a clear have-not: the bar is roughly €140 a share, and almost nothing in the evidence supports it. A quintuple from the €27.96 close means lifting market value from about €2.50bn — on 89,440,570 shares outstanding — to near €12.5bn, demanding about 17.5% compounded for a decade. That requires three things to fire at once: revenue growth, a margin climb from the 6.1% H1 FY2025/26 adjusted-EBITA trough back beyond the mid-teens, and a full multiple re-rating — all while the China premium profit pool that once powered the story is structurally contested by VBP tender economics and localization pressure. The report's own scenario work caps the optimistic case far below a quintuple: an implied €42–€49 per share over three to five years, an annualized 14%–20% and roughly 50%–75% total upside, against base and conservative paths of about 7%–10% and 2%–5% respectively. Even the bull margin target tops out near a greater-than-15% adjusted EBITA by FY2028/29, not the structural step-change a 5x would demand. To reach €140 the market would have to re-rate per-share value back toward the FY2020/21 high of €199.05 territory while the franchise is still proving it can climb out of a single-digit-margin trough. That is simply not a realistic ten-year base case for the shares. Honest verdict: no credible simultaneous path to a 10-year 5x — a clear 2/10.

On why the market hasn't "realized this," the honest read is that it largely has: the score sits in the efficiently-priced band, with a two-sided gap that is not large or exploitable. Most of the bad news is already in the tape. The shares have fallen more than 80% from the FY2020/21 high of €199.05 to €27.96, and the label has shifted, as the report puts it, from "premium structural grower" to "show me the recovery." The valuation work places today's price outside its three bands — ideal buy €24–26, acceptable hold €29–41, clearly overvalued €47–54 — with a margin of safety the report explicitly calls "not obvious," while a German 10-year Bund near 2.85%–2.86% on 25–26 June 2026 frames the equity as priced for risk rather than absurdly cheap. The mispricing, such as it is, runs both ways: bulls underweight installed-base resilience and the currency-adjusted strength of microsurgery, while bears may underestimate how lasting the China premium reset proves. A genuine narrative inflection would need two things together — a confirmed China VBP relisting of the successor bifocal IOL on workable economics, plus an H2 FY2026 adjusted-EBITA exit well above the 6.1% H1 trough; absent that, the stock can stay optically cheap for a long time. Neither side holds a large edge here. Honest verdict: roughly fairly priced for its risk, not an obvious dislocation — a 3/10.